Asset Details
Do you wish to reserve the book?
A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore
Do you wish to request the book?
A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore
2015
Overview
AimsTo compare the efficacy and safety of 3% diquafosol ophthalmic solution with those of 0.1% sodium hyaluronate ophthalmic solution in patients with dry eye in China and Singapore.MethodsA total of 497 patients with dry eye (Schirmer's test, 5 mm; fluorescein and RB score, 3 points) from China and Singapore were randomised to receive either diquafosol ophthalmic solution (diquafosol) or sodium hyaluronate ophthalmic solution (HA) at 1:1 ratio. The fluorescein staining scores and rose bengal (RB) subjective symptom scores and tear film breakup time were evaluated before treatment and 2 and 4 weeks after start of treatment.ResultsIn the diquafosol group, changes in fluorescein and RB scores compared with baseline at week 4 or at the time of discontinuation were −2.1±1.5 and −2.5±2.0, respectively. Compared with the HA group, changes in fluorescein score were non-inferior and changes in RB score were superior (p=0.019). In addition, diquafosol and HA improved tear film breakup time by 1.046±1.797 and 0.832±1.775 s, respectively (no significant intergroup difference). Adverse event onset rates were 16.3% (40 of 246 subjects) and 10.0% (25 of 251 subjects) in the diquafosol group and HA group, respectively, with borderline significant intergroup differences (p=0.046), while adverse drug reaction incidence rates were 12.2% (30 of 246 subjects) and 6.0% (15 of 251 subjects), respectively (p=0.019). Only mild adverse drug reactions (>2%) in the form of eye discharge, itching or irritation were observed.ConclusionsDiquafosol improved fluorescein staining score in a manner similar to HA, and significantly improved RB score compared with HA.Trial registration numberNCT01101984.
Publisher
BMJ Publishing Group LTD
Subject
/ Asian Continental Ancestry Group - ethnology
/ Dry Eye Syndromes - diagnosis
/ Dry Eye Syndromes - drug therapy
/ Dry Eye Syndromes - ethnology
/ Glaucoma
/ Humans
/ Hyaluronic Acid - therapeutic use
/ Polyphosphates - adverse effects
/ Polyphosphates - therapeutic use
/ Purinergic P2Y Receptor Agonists - adverse effects
/ Purinergic P2Y Receptor Agonists - therapeutic use
/ Staining and Labeling - methods
/ Uracil Nucleotides - adverse effects
